

First Trust NYSE Arca Biotechnology ETF

Ticker: FBT

Quarter End Statement of Investments

3rd Quarter as at September 30, 2025

Sector Allocation	% of Net Asset Value
Exchange-Traded Fund (First Trust NYSE® Arca® Biotechnology Index Fund [“Underlying Fund”])*	99.96%
Cash and Cash Equivalents	0.04%
Total	100.00%
Other Assets and Liabilities	-
Total Net Asset Value	100.00%

Industry Allocation of the Underlying Fund	% of Net Asset Value of the Underlying Fund
Pharmaceuticals and Biotechnology	63.31%
Other	22.25%
Medical Equipment and Services	11.24%
Electronic and Electrical Equipment	3.11%
Cash & Cash Equivalents	0.09%

Country Allocation of the Underlying Fund	% of Net Asset Value of the Underlying Fund
United States	78.25%
Switzerland	7.34%
Denmark	4.45%
The Netherlands	4.09%
Ireland	3.08%
Germany	2.71%

Holdings	% of Net Asset Value
First Trust NYSE® Arca® Biotechnology Index Fund	99.96%
Total Net Asset Value	\$1,885,527

Top 25 Holdings of the Underlying Fund	% of Net Asset Value of the Underlying Fund
Alnylam Pharmaceuticals, Inc.	4.50%
Genmab A/S (ADR)	4.45%
United Therapeutics Corporation	4.41%
BeOne Medicines Ltd. (ADR)	4.23%
argenx SE (ADR)	4.09%
Halozyme Therapeutics, Inc.	3.99%
Veracyte, Inc.	3.94%
Incyte Corporation	3.84%
Krystal Biotech, Inc.	3.70%
Corcept Therapeutics, Inc.	3.59%
Sarepta Therapeutics, Inc.	3.29%
Exact Sciences Corporation	3.27%
Neurocrine Biosciences, Inc.	3.27%
Biogen, Inc.	3.24%
Repligen Corporation	3.19%
ACADIA Pharmaceuticals, Inc.	3.16%
Gilead Sciences, Inc.	3.14%
Mettler-Toledo International, Inc.	3.12%
Natera, Inc.	3.12%
Alkermes Plc	3.08%
Regeneron Pharmaceuticals, Inc.	3.08%
Amgen, Inc.	2.97%
Illumina, Inc.	2.97%
BioMarin Pharmaceutical, Inc.	2.90%
Exelixis, Inc.	2.86%
Total Net Asset Value of the Underlying Fund (in USD)	\$1,096,405,689

*The First Trust ETF obtains exposure to the performance of an index of U.S. companies in the biotechnology industry, initially the NYSE® Arca Biotechnology Index (the “Index”) by investing in the Underlying Fund, a U.S.-listed index fund (i.e. *First Trust NYSE® Arca® Biotechnology Index Fund [the “Underlying Fund”]*) which itself replicates or substantially replicates the Index.

Commissions, management fees and expenses all may be associated with ETF investments. Please carefully read the simplified prospectus of the ETF before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Data is as of September 30, 2025 (unaudited).

(10/25)